A Phase 3 trial testing the ability of Aardvark Therapeutics’ oral treatment candidate ARD-101 to ease hyperphagia, or insatiable…
Articles by Lindsey Shapiro, PhD
Parents and siblings of people with Prader-Willi syndrome (PWS) commonly experience stress and other mental health challenges, but greater…
Throughout May, supporters will celebrate Prader-Willi Syndrome (PWS) Awareness Month with a variety of educational, advocacy, and fundraising initiatives.
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Harmony Biosciences’ pitolisant to treat daytime…
While food-seeking behaviors normally lessen as people age, they increase over time with Prader-Willi syndrome (PWS), according to a…
Prader-Willi syndrome (PWS) patients who switched from daily treatment with DCCR (diazoxide choline extended-release tablets) to a placebo experienced…
Harmony Biosciences plans to launch a Phase 3 clinical trial by year’s end to investigate whether pitolisant can safely…
Neuren Pharmaceuticals will test its therapeutic candidate NNZ-2591 in children with Prader-Willi syndrome (PWS) in a new Phase…
Researchers have determined that the role of the chemical messenger oxytocin in Prader-Willi syndrome could be associated with its…
Daily treatment with oral pitolisant reduced excessive daytime sleepiness in children and adults with Prader-Willi syndrome (PWS), according…